Anbio Biotechnology (NNNN)

Market Cap	170.74M -82.3%
Revenue (ttm)	8.65M +5.6%
Net Income	6.40M +169.9%
EPS	0.15 +161.3%
Shares Out	43.89M
PE Ratio	26.53
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,093
Open	3.640
Previous Close	3.590
Day's Range	3.510 - 4.080
52-Week Range	3.090 - 44.730
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 20, 2026

About NNNN

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Feb 19, 2025
• Employees: 27
• Stock Exchange: Nasdaq
• Ticker Symbol: NNNN
• Website: https://www.anbiobiotechnology.com

Financial Performance

In 2025, Anbio Biotechnology's revenue was $8.65 million, an increase of 5.64% compared to the previous year's $8.19 million. Earnings were $6.40 million, an increase of 169.86%.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 7, 2026

Data Sources Report a data error